Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s stock price traded up 5.2% during mid-day trading on Friday. The stock traded as high as $8.09 and last traded at $8.2150. 433,505 shares traded hands during mid-day trading, an increase of 11% from the average session volume of 389,977 shares. The stock had previously closed at $7.81.
Analysts Set New Price Targets
EPRX has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Wall Street Zen lowered Eupraxia Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Sunday, November 8th. Wedbush started coverage on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They set an "outperform" rating and a $17.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, October 15th. Finally, HC Wainwright boosted their target price on shares of Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the company a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Stock Analysis on EPRX
Eupraxia Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 12.25. The stock has a market capitalization of $548.07 million, a P/E ratio of -7.68 and a beta of 1.04. The business has a 50-day moving average price of $7.63 and a 200 day moving average price of $7.25.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.03. As a group, sell-side analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.90 EPS for the current fiscal year.
Hedge Funds Weigh In On Eupraxia Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC boosted its stake in Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company's stock worth $11,504,000 after purchasing an additional 1,289,005 shares in the last quarter. Jupiter Topco LLC bought a new stake in Eupraxia Pharmaceuticals during the 2nd quarter valued at about $6,851,000. Seven Fleet Capital Management LP bought a new stake in Eupraxia Pharmaceuticals during the 1st quarter valued at about $5,137,000. Redmile Group LLC purchased a new position in Eupraxia Pharmaceuticals in the first quarter worth about $5,068,000. Finally, Rubric Capital Management LP purchased a new position in Eupraxia Pharmaceuticals in the first quarter worth about $5,004,000.
Eupraxia Pharmaceuticals Company Profile
(
Get Free Report)
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company's lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
